BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135-1164. [PMID: 16231966 DOI: 10.2165/00003088-200544110-00003] [Cited by in Crossref: 226] [Cited by in F6Publishing: 199] [Article Influence: 15.1] [Reference Citation Analysis]
Number Citing Articles
1 Niscola P, Vischini G, Tendas A, Scaramucci L, Giovannini M, Bondanini F, Romani C, Brunetti GA, Cartoni C, Cupelli L, Ferrannini M, Perrotti A, Del Poeta G, Palumbo R, de Fabritiis P. Management of hematological malignancies in patients affected by renal failure. Expert Rev Anticancer Ther 2011;11:415-32. [PMID: 21417855 DOI: 10.1586/era.11.2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
2 Taniguchi T, Asano Y, Tamaki Z, Takahashi T, Ichimura Y, Toyama T, Kagami S, Mitsui H, Sato S. Late-onset anaphylactic reactions following i.v. cyclophosphamide pulse in a patient with systemic sclerosis and systemic lupus erythematosus overlap syndrome. J Dermatol 2014;41:912-4. [PMID: 25227247 DOI: 10.1111/1346-8138.12619] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
3 Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 2016;78:661-71. [PMID: 27646791 DOI: 10.1007/s00280-016-3152-1] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 22.6] [Reference Citation Analysis]
4 Zhai J, Zhang F, Gao S, Chen L, Feng G, Yin J, Chen W. Schisandra chinensis extract decreases chloroacetaldehyde production in rats and attenuates cyclophosphamide toxicity in liver, kidney and brain. J Ethnopharmacol 2018;210:223-31. [PMID: 28821392 DOI: 10.1016/j.jep.2017.08.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
5 Campagne O, Zhong B, Nair S, Lin T, Huang J, Onar-Thomas A, Robinson G, Gajjar A, Stewart CF. Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. Clin Cancer Res 2020;26:1563-73. [PMID: 31796512 DOI: 10.1158/1078-0432.CCR-19-2685] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Rodriguez-frias EA, Lee WM. Cancer Chemotherapy II: Atypical Hepatic Injuries. Clinics in Liver Disease 2007;11:663-76. [DOI: 10.1016/j.cld.2007.06.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
7 Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol 2017;13:901-23. [PMID: 28766962 DOI: 10.1080/17425255.2017.1360277] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
8 Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH; EORTC-PAMM-NDDG. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 2007;46:1051-68. [PMID: 18027989 DOI: 10.2165/00003088-200746120-00005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
9 Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WS. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther 2013;20:521-30. [PMID: 23928731 DOI: 10.1038/cgt.2013.49] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
10 Huyan XH, Yang YP, Fan YM, Huang WM, Li W, Zhou Y. Cutaneous and systemic pathogenicity of a clinical isolate of Cladosporium sphaerospermum in a murine model. J Comp Pathol 2012;147:354-9. [PMID: 22516085 DOI: 10.1016/j.jcpa.2012.01.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Qu N, Kuramasu M, Hirayanagi Y, Nagahori K, Hayashi S, Ogawa Y, Terayama H, Suyama K, Naito M, Sakabe K, Itoh M. Gosha-Jinki-Gan Recovers Spermatogenesis in Mice with Busulfan-Induced Aspermatogenesis. Int J Mol Sci 2018;19:E2606. [PMID: 30177609 DOI: 10.3390/ijms19092606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
12 Brooks JD, Teraoka SN, Bernstein L, Mellemkjær L, Malone KE, Lynch CF, Haile RW, Concannon P, Reiner AS, Duggan DJ, Schiermeyer K, Bernstein JL, Figueiredo JC; WECARE Study Collaborative Group. Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study. Cancer Causes Control 2013;24:1605-14. [PMID: 23775025 DOI: 10.1007/s10552-013-0237-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
13 Shu W, Wang X, Yang X, Liang L, Li J, Chen Z, Chen X, Jin J, Li R, Zhao L, Huang M. Simultaneous determination of cyclophosphamide and 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry – application to Chinese systemic lupus erythematosus patients. Clinical Chemistry and Laboratory Medicine (CCLM) 2011;49. [DOI: 10.1515/cclm.2011.710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Liang L, Chen D, Wang X, Yang Z, Zhou J, Zhan Z, Lian F. Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic Diseases. Drugs Real World Outcomes 2017;4:175-82. [PMID: 28646351 DOI: 10.1007/s40801-017-0112-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Audemard-Verger A, Martin Silva N, Verstuyft C, Costedoat-Chalumeau N, Hummel A, Le Guern V, Sacré K, Meyer O, Daugas E, Goujard C, Sultan A, Lobbedez T, Galicier L, Pourrat J, Le Hello C, Godin M, Morello R, Lambert M, Hachulla E, Vanhille P, Queffeulou G, Potier J, Dion JJ, Bataille P, Chauveau D, Moulis G, Farge-Bancel D, Duhaut P, Saint-Marcoux B, Deroux A, Manuzak J, Francès C, Aumaitre O, Bezanahary H, Becquemont L, Bienvenu B. Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. PLoS One 2016;11:e0151696. [PMID: 27002825 DOI: 10.1371/journal.pone.0151696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
16 Ekhart C, Gebretensae A, Rosing H, Rodenhuis S, Beijnen JH, Huitema AD. Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 2007;854:345-9. [PMID: 17485255 DOI: 10.1016/j.jchromb.2007.04.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
17 Wang CC, Weng TI, Wu ET, Wu MH, Yang RS, Liu SH. Involvement of interleukin-6-regulated nitric oxide synthase in hemorrhagic cystitis and impaired bladder contractions in young rats induced by acrolein, a urinary metabolite of cyclophosphamide. Toxicol Sci 2013;131:302-10. [PMID: 22961095 DOI: 10.1093/toxsci/kfs270] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
18 Mills KA, West EJ, Grundy L, Mcdermott C, Sellers DJ, Rose’myer RB, Chess-williams R. Hypersensitivity of bladder low threshold, wide dynamic range, afferent fibres following treatment with the chemotherapeutic drugs cyclophosphamide and ifosfamide. Arch Toxicol 2020;94:2785-97. [DOI: 10.1007/s00204-020-02773-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Lee HY, Park YM, Kim J, Oh HG, Kim KS, Kang HJ, Kim RR, Kim MJ, Kim SH, Yang HJ, Oh J. Orostachys japonicus A. Berger Extracts Induce Immunity-Enhancing Effects on Cyclophosphamide-Treated Immunosuppressed Rats. Biomed Res Int 2019;2019:9461960. [PMID: 30723745 DOI: 10.1155/2019/9461960] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment: SNP and treatment effect of multiple myeloma. European Journal of Haematology 2012;88:93-117. [DOI: 10.1111/j.1600-0609.2011.01696.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
21 Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70:1564-1572. [PMID: 20145127 DOI: 10.1158/0008-5472.can-09-3228] [Cited by in Crossref: 154] [Cited by in F6Publishing: 110] [Article Influence: 14.0] [Reference Citation Analysis]
22 Ekhart C, Rodenhuis S, Beijnen JH, Huitema AD. Carbamazepine induces bioactivation of cyclophosphamide and thiotepa. Cancer Chemother Pharmacol 2009;63:543-7. [PMID: 18437385 DOI: 10.1007/s00280-008-0758-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008;18:515-23. [PMID: 18496131 DOI: 10.1097/FPC.0b013e3282fc9766] [Cited by in Crossref: 82] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
24 Joseph KB, Awadallah N, Delay ER, Delay RJ. Transient Effects of Cyclophosphamide on Basal Cell Proliferation of Olfactory Epithelia. Chem Senses 2020;45:549-61. [PMID: 32531016 DOI: 10.1093/chemse/bjaa039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, Bins A, Tan HL, Harper JV, Hassan NJ, Jakobsen BK, Jorritsma A, Blank CU, Schumacher TN, Haanen JB. Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. Mol Ther 2015;23:1541-50. [PMID: 25896248 DOI: 10.1038/mt.2015.60] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 11.5] [Reference Citation Analysis]
26 Meng Y, Xu Z, Wu F, Chen W, Xie S, Liu J, Huang X, Zhou Y. Sphingosine-1-phosphate suppresses cyclophosphamide induced follicle apoptosis in human fetal ovarian xenografts in nude mice☆. Fertility and Sterility 2014;102:871-877.e3. [DOI: 10.1016/j.fertnstert.2014.05.040] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
27 Helsby N, Yong M, Burns K, Findlay M, Porter D. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. Cancer Chemother Pharmacol 2021;88:533-42. [PMID: 34114066 DOI: 10.1007/s00280-021-04307-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Jahromi SR, Sahraian MA, Ashtari F, Ayromlou H, Etemadifar M, Ghaffarpour M, Mohammadianinejad E, Nafissi S, Nickseresht A, Shaygannejad V, Togha M, Torabi HR, Ziaie S. Islamic fasting and multiple sclerosis. BMC Neurol 2014;14:56. [PMID: 24655543 DOI: 10.1186/1471-2377-14-56] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
29 Ahmed JH, Makonnen E, Bisaso RK, Mukonzo JK, Fotoohi A, Aseffa A, Howe R, Hassan M, Aklillu E. Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. Front Pharmacol 2020;11:406. [PMID: 32390827 DOI: 10.3389/fphar.2020.00406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Hamadah AM, Thanarajasingam G, Gharaibeh KA, Finnes HD, Thompson CA, Leung N. Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis. Leuk Lymphoma 2017;58:457-60. [PMID: 27268591 DOI: 10.1080/10428194.2016.1190977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
31 Fierro ME, Datta P, Rewers-Felkins K, Smillie CM, Bresnahan A, Baker T, Hale TW. Cyclophosphamide Use in Multiple Sclerosis: Levels Detected in Human Milk. Breastfeed Med 2019;14:128-30. [PMID: 30589584 DOI: 10.1089/bfm.2018.0137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
32 Thakur A, Parvez MM, Leeder JS, Prasad B. Ontogeny of Drug-Metabolizing Enzymes. Methods Mol Biol 2021;2342:551-93. [PMID: 34272706 DOI: 10.1007/978-1-0716-1554-6_18] [Reference Citation Analysis]
33 Takahashi T, Scheibner A, Cao Q, Pearson R, Sanghavi K, Weisdorf DJ, Brunstein CG, Rogosheske J, Bachanova V, Warlick ED, Wiseman A, Jacobson PA. Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. Transplant Cell Ther 2021;27:773.e1-8. [PMID: 34044184 DOI: 10.1016/j.jtct.2021.05.013] [Reference Citation Analysis]
34 Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treat Rev 2016;50:247-63. [PMID: 27776286 DOI: 10.1016/j.ctrv.2016.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
35 Sottani C, Porro B, Imbriani M, Minoia C. Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicol Lett 2012;213:107-15. [PMID: 21477641 DOI: 10.1016/j.toxlet.2011.03.028] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
36 Lee JY, Lee YM, Kim TK, Choi K, Zoh KD. Degradation of cyclophosphamide during UV/chlorine reaction: Kinetics, byproducts, and their toxicity. Chemosphere 2021;268:128817. [PMID: 33162158 DOI: 10.1016/j.chemosphere.2020.128817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treatment Reviews 2009;35:18-31. [DOI: 10.1016/j.ctrv.2008.07.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
38 Hrynchak I, Sousa E, Pinto M, Costa VM. The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. Drug Metabolism Reviews 2017;49:158-96. [DOI: 10.1080/03602532.2017.1316285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
39 Upton A, McCune JS, Kirby KA, Leisenring W, McDonald G, Batchelder A, Marr KA. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13:760-4. [PMID: 17580253 DOI: 10.1016/j.bbmt.2007.03.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
40 Ekiz Yılmaz T, Taşdemir M, Kaya M, Arıcan N, Ahıshalı B. The effects of magnesium sulfate on cyclophosphamide-induced ovarian damage: Folliculogenesis. Acta Histochem 2020;122:151470. [PMID: 31812447 DOI: 10.1016/j.acthis.2019.151470] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Liu F, Li XL, Lin T, He DW, Wei GH, Liu JH, Li LS. The cyclophosphamide metabolite, acrolein, induces cytoskeletal changes and oxidative stress in Sertoli cells. Mol Biol Rep 2012;39:493-500. [PMID: 21553225 DOI: 10.1007/s11033-011-0763-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
42 Ayhanci A, Uyar R, Aral E, Kabadere S, Appak S. Protective Effect of Zinc on Cyclophosphamide-Induced Hematoxicity and Urotoxicity. Biol Trace Elem Res 2008;126:186-93. [DOI: 10.1007/s12011-008-8189-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
43 Steinbrecht S, Kiebist J, König R, Thiessen M, Schmidtke KU, Kammerer S, Küpper JH, Scheibner K. Synthesis of cyclophosphamide metabolites by a peroxygenase from Marasmius rotula for toxicological studies on human cancer cells. AMB Express 2020;10:128. [PMID: 32683510 DOI: 10.1186/s13568-020-01064-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
44 Ozolins̆ TR. Cyclophosphamide and the Teratology society: an awkward marriage. Birth Defects Research Part B: Developmental and Reproductive Toxicology 2010;89:289-99. [DOI: 10.1002/bdrb.20255] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
45 Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008;9:598-610. [PMID: 18781911 DOI: 10.2174/138920008785821710] [Cited by in Crossref: 219] [Cited by in F6Publishing: 207] [Article Influence: 16.8] [Reference Citation Analysis]
46 Lu WP, Mei XT, Wang Y, Zheng YP, Xue YF, Xu DH. Zn(II)-curcumin protects against oxidative stress, deleterious changes in sperm parameters and histological alterations in a male mouse model of cyclophosphamide-induced reproductive damage. Environ Toxicol Pharmacol 2015;39:515-24. [PMID: 25681702 DOI: 10.1016/j.etap.2014.12.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
47 Wang A, Kligerman AD, Holladay SD, Wolf DC, Robertson JL. Arsenate and dimethylarsinic acid in drinking water did not affect DNA damage repair in urinary bladder transitional cells or micronuclei in bone marrow. Environ Mol Mutagen 2009;50:760-70. [DOI: 10.1002/em.20496] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
48 Campagne O, Davis A, Zhong B, Nair S, Haberman V, T Patel Y, Janke L, F Roussel M, Stewart C. CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice. J Pharm Pharm Sci 2019;22:612-29. [PMID: 31815662 DOI: 10.18433/jpps30608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Zhai J, Zhang F, Gao S, Chen L, Feng G, Yin J, Chen W. Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats. Molecules 2017;22:E1298. [PMID: 28786954 DOI: 10.3390/molecules22081298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Rymarz A, Matyjek A, Sułek-Jakóbczyk M, Mosakowska M, Niemczyk S. Impaired Kidney Function Associated with Increased Risk of Side Effects in Patients with Small Vessel Vasculitis Treated with Rituximab as an Induction Therapy. J Clin Med 2021;10:786. [PMID: 33669267 DOI: 10.3390/jcm10040786] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 van den Berg H, van den Anker JN, Beijnen JH. Cytostatic drugs in infants: A review on pharmacokinetic data in infants. Cancer Treatment Reviews 2012;38:3-26. [DOI: 10.1016/j.ctrv.2011.03.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
52 Hutson JR, Weitzman S, Schechter T, Arceci RJ, Kim RB, Finkelstein Y. Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. Expert Opin Drug Metab Toxicol 2012;8:709-22. [PMID: 22509821 DOI: 10.1517/17425255.2012.680884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, Nauntofte B. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2008;106:217-26. [DOI: 10.1016/j.tripleo.2008.04.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
54 Hirayanagi Y, Qu N, Hirai S, Naito M, Terayama H, Hayashi S, Hatayama N, Kuramasu M, Ogawa Y, Itoh M. Busulfan pretreatment for transplantation of rat spermatogonia differentially affects immune and reproductive systems in male recipient mice. Anat Sci Int 2015;90:264-74. [PMID: 25412587 DOI: 10.1007/s12565-014-0261-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kohandel Z, Farkhondeh T, Aschner M, Samarghandian S. Anti-inflammatory effects of thymoquinone and its protective effects against several diseases. Biomed Pharmacother 2021;138:111492. [PMID: 33743334 DOI: 10.1016/j.biopha.2021.111492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS One 2016;11:e0166891. [PMID: 27907031 DOI: 10.1371/journal.pone.0166891] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
57 de Castro FA, Simões BP, Coelho EB, Lanchote VL. Enantioselectivity in the Metabolism of Cyclophosphamide in Patients With Multiple or Systemic Sclerosis. J Clin Pharmacol 2017;57:784-95. [PMID: 28083951 DOI: 10.1002/jcph.863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Kulkarni NN, Adase CA, Zhang LJ, Borkowski AW, Li F, Sanford JA, Coleman DJ, Aguilera C, Indra AK, Gallo RL. IL-1 Receptor-Knockout Mice Develop Epidermal Cysts and Show an Altered Innate Immune Response after Exposure to UVB Radiation. J Invest Dermatol 2017;137:2417-26. [PMID: 28754339 DOI: 10.1016/j.jid.2017.07.814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
59 Li J, Ma Z, Jiang RW, Wu B. Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs. Expert Opin Drug Metab Toxicol 2013;9:1085-95. [PMID: 23687971 DOI: 10.1517/17425255.2013.802771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Halpert JR. Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back. Drug Metab Dispos 2011;39:1113-21. [PMID: 21502194 DOI: 10.1124/dmd.111.039719] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
61 Boos JA, Misun PM, Michlmayr A, Hierlemann A, Frey O. Microfluidic Multitissue Platform for Advanced Embryotoxicity Testing In Vitro. Adv Sci (Weinh) 2019;6:1900294. [PMID: 31380185 DOI: 10.1002/advs.201900294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
62 Almeer RS, Alnasser M, Aljarba N, AlBasher GI. Effects of Green cardamom (Elettaria cardamomum Maton) and its combination with cyclophosphamide on Ehrlich solid tumors. BMC Complement Med Ther 2021;21:133. [PMID: 33926427 DOI: 10.1186/s12906-021-03305-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Olayinka ET, Ore A, Ola OS, Adeyemo OA. Ameliorative Effect of Gallic Acid on Cyclophosphamide-Induced Oxidative Injury and Hepatic Dysfunction in Rats. Med Sci (Basel) 2015;3:78-92. [PMID: 29083393 DOI: 10.3390/medsci3030078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
64 Nagar S. Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. Adv Exp Med Biol 2010;678:124-32. [PMID: 20738014 DOI: 10.1007/978-1-4419-6306-2_16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
65 Zhang Y, Han Y, He J, Ouyang K, Zhao M, Cai L, Zhao Z, Meng W, Chen L, Wang W. Digestive properties and effects of Chimonanthus nitens Oliv polysaccharides on antioxidant effects in vitro and in immunocompromised mice. Int J Biol Macromol 2021;185:306-16. [PMID: 34166692 DOI: 10.1016/j.ijbiomac.2021.06.114] [Reference Citation Analysis]
66 Ramirez DA, Collins KP, Aradi AE, Conger KA, Gustafson DL. Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics. Drug Metab Dispos 2019;47:257-68. [PMID: 30567881 DOI: 10.1124/dmd.118.083766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
67 Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 2011;4:111-21. [PMID: 21694808 DOI: 10.1177/1756285611398939] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
68 Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U. Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. Clin Pharmacokinet 2007;46:319-33. [PMID: 17375983 DOI: 10.2165/00003088-200746040-00005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
69 Mukherjee N, Delay E. Cyclophosphamide-induced disruption of umami taste functions and taste epithelium. Neuroscience 2011;192:732-45. [DOI: 10.1016/j.neuroscience.2011.07.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
70 Johnson SE, Ugolkov A, Haney CR, Bondarenko G, Li L, Waters EA, Bergan R, Tran A, O'Halloran TV, Mazar A, Zhao M. Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity. Clin Cancer Res 2019;25:1331-42. [PMID: 30420445 DOI: 10.1158/1078-0432.CCR-18-1846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Pinto N, Navarro SL, Rimorin C, Wurscher M, Hawkins DS, McCune JS. Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2021;:e29203. [PMID: 34245211 DOI: 10.1002/pbc.29203] [Reference Citation Analysis]
72 Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, De Zoysa JZ, Tingle MD. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol 2010;70:844-53. [PMID: 21175440 DOI: 10.1111/j.1365-2125.2010.03789.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
73 Morano A, Iannone L, Palleria C, Fanella M, Giallonardo AT, De Sarro G, Russo E, Di Bonaventura C. Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy. Expert Opin Pharmacother 2019;20:25-39. [PMID: 30403892 DOI: 10.1080/14656566.2018.1541349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
74 Karadag AS, Aslan Kayıran M, Lotti T, Wollina U. Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. Dermatol Ther 2020;33:e13686. [PMID: 32458530 DOI: 10.1111/dth.13686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
75 Fernandes BJ, Silva Cde M, Andrade JM, Matthes Ado C, Coelho EB, Lanchote VL. Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. Cancer Chemother Pharmacol 2011;68:897-904. [PMID: 21290248 DOI: 10.1007/s00280-011-1554-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
76 Harahap Y, Yanuar A, Muhammad C, Melhan M, Purwanto DJ. Quantification of 3-Hydroxypropyl Mercapturic Acid in the Urine of Patients with Breast Cancer to Monitor Cyclophosphamide Toxicity. Therapeutic Drug Monitoring 2020;42:548-53. [DOI: 10.1097/ftd.0000000000000737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
77 Hsieh SG, Hibbert S, Shaw P, Ahern V, Arora M. Association of cyclophosphamide use with dental developmental defects and salivary gland dysfunction in recipients of childhood antineoplastic therapy. Cancer 2011;117:2219-27. [PMID: 21523736 DOI: 10.1002/cncr.25704] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
78 Sadeghi B, Al-chaqmaqchi H, Al-hashmi S, Brodin D, Hassan Z, Abedi-valugerdi M, Moshfegh A, Hassan M. Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target? Bone Marrow Transplant 2013;48:284-93. [DOI: 10.1038/bmt.2012.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
79 Anan HH, Zidan RA, Abd El-baset SA, Ali MM. Ameliorative effect of zinc oxide nanoparticles on cyclophosphamide induced testicular injury in adult rat. Tissue and Cell 2018;54:80-93. [DOI: 10.1016/j.tice.2018.08.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
80 M Castillejo Becerra C, Ding Y, Kenol B, Hendershot A, Meara AS. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmol 2020;5:e000331. [PMID: 32154367 DOI: 10.1136/bmjophth-2019-000331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
81 Sato H, Shirai T, Fujii H, Ishii T, Harigae H. Cyclophosphamide-associated enteritis presenting with severe protein-losing enteropathy in granulomatosis with polyangiitis: A case report. World J Gastroenterol 2021; 27(20): 2657-2663 [PMID: 34092982 DOI: 10.3748/wjg.v27.i20.2657] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Awadallah N, Proctor K, Joseph KB, Delay ER, Delay RJ. Cyclophosphamide has Long-Term Effects on Proliferation in Olfactory Epithelia. Chem Senses 2020;45:97-109. [PMID: 31844905 DOI: 10.1093/chemse/bjz075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
83 Zekić T, Benić MS, Antulov R, Antončić I, Novak S. The multifactorial origin of posterior reversible encephalopathy syndrome in cyclophosphamide-treated lupus patients. Rheumatol Int 2017;37:2105-14. [PMID: 29043491 DOI: 10.1007/s00296-017-3843-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
84 Hassan M, Andersson BS. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics 2013;14:75-87. [PMID: 23252950 DOI: 10.2217/pgs.12.185] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
85 Balasubramanian P, Desire S, Panetta JC, Lakshmi KM, Mathews V, George B, Viswabandya A, Chandy M, Krishnamoorthy R, Srivastava A. Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. Bone Marrow Transplant 2012;47:1178-85. [DOI: 10.1038/bmt.2011.254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
86 Opdam FL, Gelderblom H, Guchelaar H. Phenotyping drug disposition in oncology. Cancer Treatment Reviews 2012;38:715-25. [DOI: 10.1016/j.ctrv.2011.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
87 Kim J, Chan JJ. Cyclophosphamide in dermatology. Australas J Dermatol 2017;58:5-17. [PMID: 26806212 DOI: 10.1111/ajd.12406] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
88 Sabik LM, Abd El-rahman SS. Alpha-tocopherol and ginger are protective on Cyclophosphamide-induced gonadal toxicity in adult male albino rats. Basic and Applied Pathology 2009;2:21-9. [DOI: 10.1111/j.1755-9294.2009.01034.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
89 Silva CDM, Fernandes BJD, Donadi EA, Silva LM, Coelho EB, Dantas M, Marques MP, Lanchote VL. Influence of Glomerular Filtration Rate on the Pharmacokinetics of Cyclophosphamide Enantiomers in Patients With Lupus Nephritis. The Journal of Clinical Pharmacology 2009;49:965-72. [DOI: 10.1177/0091270009337938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
90 Salimi A, Pirhadi R, Jamali Z, Ramazani M, Yousefsani BS, Pourahmad J. Mitochondrial and lysosomal protective agents ameliorate cytotoxicity and oxidative stress induced by cyclophosphamide and methotrexate in human blood lymphocytes. Hum Exp Toxicol 2019;38:1266-74. [PMID: 31446784 DOI: 10.1177/0960327119871096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
91 Seong SS, Choi CB, Yun HR, Kim YJ, Sung YK, Bae SC. Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis. Rheumatol Int 2008;28:453-8. [PMID: 17924111 DOI: 10.1007/s00296-007-0464-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 McCune JS, Jacobson P, Wiseman A, Militano O. Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. Bone Marrow Transplant 2015;50:165-72. [PMID: 25347008 DOI: 10.1038/bmt.2014.235] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
93 Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: Old weapon for new battle. Semin Cancer Biol 2021;68:8-20. [PMID: 31550502 DOI: 10.1016/j.semcancer.2019.09.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
94 Fan KJ, Li YW, Wu J, Li J, Zhang J, Wang QS, Xu BX, Cai Q, Wang TY. The Traditional Chinese Medicine Fufang Shatai Heji (STHJ) Enhances Immune Function in Cyclophosphamide-Treated Mice. Evid Based Complement Alternat Med 2020;2020:3849847. [PMID: 32063984 DOI: 10.1155/2020/3849847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review. Cancer Sci 2021;112:2607-24. [PMID: 33938097 DOI: 10.1111/cas.14933] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Attia DHS, Eissa M, Samy LA, Khattab RA. Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis. Clin Rheumatol 2021;40:753-62. [PMID: 32661806 DOI: 10.1007/s10067-020-05276-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Pinto N, Ludeman SM, Dolan ME. Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 2009;10:1897-903. [PMID: 19958089 DOI: 10.2217/pgs.09.134] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
98 Janus N, Launay-Vacher V, Deray G, Thyss A, Thariat J. [Management of chemotherapy in hemodialysis patients]. Bull Cancer 2012;99:371-80. [PMID: 22133734 DOI: 10.1684/bdc.2011.1483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
99 Yu J, Shi F, Hu S. Improved immune responses to a bivalent vaccine of Newcastle disease and avian influenza in chickens by ginseng stem-leaf saponins. Veterinary Immunology and Immunopathology 2015;167:147-55. [DOI: 10.1016/j.vetimm.2015.07.017] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
100 Collongues N, Ayme-Dietrich E, Monassier L, de Seze J. Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. Drugs 2019;79:125-42. [PMID: 30623348 DOI: 10.1007/s40265-018-1039-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 17.0] [Reference Citation Analysis]
101 Frey O, Misun PM, Fluri DA, Hengstler JG, Hierlemann A. Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis. Nat Commun 2014;5:4250. [PMID: 24977495 DOI: 10.1038/ncomms5250] [Cited by in Crossref: 219] [Cited by in F6Publishing: 197] [Article Influence: 31.3] [Reference Citation Analysis]
102 Ekhart C, Rodenhuis S, Beijnen JH, Huitema ADR. Pharmacokinetics of Cyclophosphamide and Thiotepa in a Conventional Fractionated High-Dose Regimen Compared With a Novel Simplified Unfractionated Regimen. Therapeutic Drug Monitoring 2009;31:95-103. [DOI: 10.1097/ftd.0b013e318194e484] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
103 Di L, Balesano A, Jordan S, Shi SM. The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation. AAPS J 2021;23. [DOI: 10.1208/s12248-020-00536-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
104 Wang HN, Zhu XY, Zhu Y, Xie QH, Lai LY, Zhao M, Chen YC, Xue J, Hao CM, Gu Y, Lin SY. The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. Clin Immunol 2015;160:342-8. [PMID: 26222310 DOI: 10.1016/j.clim.2015.07.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
105 . Leukemia from Dermal Exposure to Cyclophosphamide among Nurses in the Netherlands: Quantitative Assessment of the Risk. The Annals of Occupational Hygiene 2014. [DOI: 10.1093/annhyg/met077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
106 Li Y, Fu S, Hu W, Liu J, Finkel K, Gershenson D, Kavanagh J. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2007;17:739-63. [DOI: 10.1111/j.1525-1438.2007.00847.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
107 Figueroa D, Asaduzzaman M, Young F. Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines In Vitro. Biomed Res Int 2019;2019:6146972. [PMID: 30766885 DOI: 10.1155/2019/6146972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Kim I, Yun H, Choi B, Han N, Kim MG, Park S, Oh JM. Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. Eur J Clin Pharmacol 2013;69:1543-51. [DOI: 10.1007/s00228-013-1507-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
109 Gernaat SAM, von Stedingk H, Hassan M, Nilsson HP, Rodriguez-Wallberg KA, Hedayati E, Rydberg P. Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study. Sci Rep 2021;11:2707. [PMID: 33526812 DOI: 10.1038/s41598-021-81662-1] [Reference Citation Analysis]
110 Koklu H, Tufan A, Erkul Y, Akyurek N, Civelek R. Secondary acute myeloid leukemia arising early after cyclophosphamide treatment. Int J Clin Pharm 2015;37:289-91. [DOI: 10.1007/s11096-015-0069-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
111 Swystun LL, Mukherjee S, Levine M, Liaw PC. The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal-based and cell-based models: In vitro and in vivo studies of the procoagulant effects of acrolein. Journal of Thrombosis and Haemostasis 2011;9:767-75. [DOI: 10.1111/j.1538-7836.2011.04232.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
112 Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008;18:1009-15. [PMID: 18854779 DOI: 10.1097/FPC.0b013e328313aaa4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
113 van Laar JM, Simms RW. Immunomodulatory, Immunoablative, and Biologic Therapies. In: Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M, editors. Scleroderma. Cham: Springer International Publishing; 2017. pp. 567-82. [DOI: 10.1007/978-3-319-31407-5_41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
114 Ramadan G, El-Beih NM, Abd El-Kareem HF. Anti-metabolic syndrome and immunostimulant activities of Egyptian fenugreek seeds in diabetic/obese and immunosuppressive rat models. Br J Nutr 2011;105:995-1004. [PMID: 21205429 DOI: 10.1017/S0007114510004708] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
115 Broto M, Mccabe R, Galve R, Marco M. A high-specificity immunoassay for the therapeutic drug monitoring of cyclophosphamide. Analyst 2019;144:5172-8. [DOI: 10.1039/c9an00576e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
116 Perini P, Calabrese M, Rinaldi L, Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opinion on Drug Safety 2007;6:183-90. [DOI: 10.1517/14740338.6.2.183] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
117 McCune JS, Bemer MJ. Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. Clin Pharmacokinet 2016;55:525-50. [PMID: 26563168 DOI: 10.1007/s40262-015-0339-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
118 Bubalo JS, Cherala G, Mccune JS, Munar MY, Tse S, Maziarz R. Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation. The Journal of Clinical Pharmacology 2012;52:586-94. [DOI: 10.1177/0091270011398243] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
119 Kawakami T, Nakamura Y, Karibe H. Cyclophosphamide inhibits root development of molar teeth in growing mice. Odontology 2015;103:143-51. [DOI: 10.1007/s10266-014-0158-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
120 Thu KK, Lwin AA, Maw KT, Htay LL, Myint KM, Soe MM, Linn YH, Soe C, Win NHH. Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients. Drugs Ther Perspect 2019;35:334-40. [DOI: 10.1007/s40267-019-00631-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Roofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials. Journal of Scleroderma and Related Disorders 2020;5:61-71. [DOI: 10.1177/2397198320903208] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 20.0] [Reference Citation Analysis]
122 Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018;24:937-44. [PMID: 29374527 DOI: 10.1016/j.bbmt.2018.01.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
123 Huang B, Xiao L, Dong H, Zhang X, Gan W, Mahboob S, Al-ghanim KA, Yuan Q, Li Y. Electrochemical sensing platform based on molecularly imprinted polymer decorated N,S co-doped activated graphene for ultrasensitive and selective determination of cyclophosphamide. Talanta 2017;164:601-7. [DOI: 10.1016/j.talanta.2016.11.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
124 Rofaiel S, Muo EN, Mousa SA. Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmgenomics Pers Med 2010;3:129-43. [PMID: 23226048 DOI: 10.2147/PGPM.S10789] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet 2009;54:564-71. [PMID: 19696793 DOI: 10.1038/jhg.2009.79] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
126 de Witte M, Daenen LGM, van der Wagen L, van Rhenen A, Raymakers R, Westinga K, Kuball J. Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust. Hemasphere 2021;5:e580. [PMID: 34095763 DOI: 10.1097/HS9.0000000000000580] [Reference Citation Analysis]
127 Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008;16:1665-73. [PMID: 18665155 DOI: 10.1038/mt.2008.162] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 6.5] [Reference Citation Analysis]
128 Hon C, Teschke K, Shen H, Demers PA, Venners S. Antineoplastic drug contamination in the urine of Canadian healthcare workers. Int Arch Occup Environ Health 2015;88:933-41. [DOI: 10.1007/s00420-015-1026-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
129 Kang SM, Kim D, Lee JH, Takayama S, Park JY. Engineered Microsystems for Spheroid and Organoid Studies. Adv Healthc Mater 2021;10:e2001284. [PMID: 33185040 DOI: 10.1002/adhm.202001284] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
130 Sadeghi B, Jansson M, Hassan Z, Mints M, Hägglund H, Abedi-Valugerdi M, Hassan M. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model. Bone Marrow Transplant 2008;41:895-904. [PMID: 18223695 DOI: 10.1038/sj.bmt.1705996] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
131 Yang L, Zhang XC, Yu SF, Zhu HQ, Hu AP, Chen J, Shen P. Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. BMC Cancer 2015;15:917. [PMID: 26582454 DOI: 10.1186/s12885-015-1932-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
132 Helsby NA, Yong M, van Kan M, de Zoysa JR, Burns KE. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. Br J Clin Pharmacol 2019;85:1925-34. [PMID: 31218720 DOI: 10.1111/bcp.14031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
133 Henning RJ, Johnson GT, Coyle JP, Harbison RD. Acrolein Can Cause Cardiovascular Disease: A Review. Cardiovasc Toxicol 2017;17:227-36. [PMID: 28084565 DOI: 10.1007/s12012-016-9396-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 16.3] [Reference Citation Analysis]
134 de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006;94:1226-30. [PMID: 16622453 DOI: 10.1038/sj.bjc.6603097] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
135 Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RA. Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Drug Metab Dispos 2012;40:54-63. [PMID: 21976622 DOI: 10.1124/dmd.111.039347] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
136 Bhatt DK, Gaedigk A, Pearce RE, Leeder JS, Prasad B. Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver. Drug Metab Dispos 2017;45:1044-8. [PMID: 28607029 DOI: 10.1124/dmd.117.076463] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
137 Gay SC, Roberts AG, Halpert JR. Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. Future Med Chem 2010;2:1451-68. [PMID: 21103389 DOI: 10.4155/fmc.10.229] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.3] [Reference Citation Analysis]
138 Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Sahraian MA, Shapiro L. Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment. Mult Scler Relat Disord 2019;39:101906. [PMID: 31887565 DOI: 10.1016/j.msard.2019.101906] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
139 Yang Y, Hu T, Li J, Xin M, Zhao X. Structural characterization and effect on leukopenia of fucoidan from Durvillaea antarctica. Carbohydr Polym 2021;256:117529. [PMID: 33483047 DOI: 10.1016/j.carbpol.2020.117529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
140 Zheng PP, Li J, Kros JM. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev 2018;38:325-76. [PMID: 28862319 DOI: 10.1002/med.21463] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
141 Croyle L, Morand EF. Optimizing the use of existing therapies in lupus. Int J Rheum Dis 2015;18:129-37. [DOI: 10.1111/1756-185x.12551] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
142 Bein K, Leikauf GD. ACROLEIN AND UNSATURATED ALDEHYDES. In: Lippmann M, Leikauf GD, editors. Environmental Toxicants. Wiley; 2020. pp. 205-59. [DOI: 10.1002/9781119438922.ch7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
143 Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21:1395-1403. [PMID: 20118214 DOI: 10.1093/annonc/mdp598] [Cited by in Crossref: 102] [Cited by in F6Publishing: 71] [Article Influence: 9.3] [Reference Citation Analysis]
144 Langmia IM, Just KS, Yamoune S, Brockmöller J, Masimirembwa C, Stingl JC. CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy. Front Genet 2021;12:692234. [PMID: 34322158 DOI: 10.3389/fgene.2021.692234] [Reference Citation Analysis]
145 van Eijk M, Boosman RJ, Schinkel AH, Huitema ADR, Beijnen JH. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. Cancer Chemother Pharmacol. 2019;84:487-499. [PMID: 31309254 DOI: 10.1007/s00280-019-03905-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
146 Tong J, Mo QG, Ma BX, Ge LL, Zhou G, Wang YW. The protective effects of Cichorium glandulosum seed and cynarin against cyclophosphamide and its metabolite acrolein-induced hepatotoxicity in vivo and in vitro. Food Funct 2017;8:209-19. [PMID: 27966724 DOI: 10.1039/c6fo01531j] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
147 Anderson B, Sawyer DB. Predicting and preventing the cardiotoxicity of cancer therapy. Expert Review of Cardiovascular Therapy 2014;6:1023-33. [DOI: 10.1586/14779072.6.7.1023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
148 Bénit CP, Vecht CJ. Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids. Neurooncol Pract 2016;3:245-60. [PMID: 31385988 DOI: 10.1093/nop/npv038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
149 Cocozza F, Menay F, Tsacalian R, Elisei A, Sampedro P, Soria I, Waldner C, Gravisaco MJ, Mongini C. Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma. Vaccine 2019;37:1565-76. [PMID: 30777349 DOI: 10.1016/j.vaccine.2019.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
150 Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 2013;5:826-37. [PMID: 23933992 DOI: 10.4161/mabs.26008] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 9.0] [Reference Citation Analysis]
151 Hadamitzky M, Lückemann L, Pacheco-lópez G, Schedlowski M. Pavlovian Conditioning of Immunological and Neuroendocrine Functions. Physiological Reviews 2020;100:357-405. [DOI: 10.1152/physrev.00033.2018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 17.0] [Reference Citation Analysis]
152 Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ, Hawkins DS. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer 2012;118:1130-7. [PMID: 21761400 DOI: 10.1002/cncr.26358] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
153 McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, Schoch HG, McDonald GB. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant. 2007;13:853-862. [PMID: 17580264 DOI: 10.1016/j.bbmt.2007.03.012] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
154 Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients. JNCI: Journal of the National Cancer Institute 2008;100:1058-67. [DOI: 10.1093/jnci/djn206] [Cited by in Crossref: 109] [Cited by in F6Publishing: 86] [Article Influence: 8.4] [Reference Citation Analysis]
155 Broto M, Galve R, Marco M. Bioanalytical methods for cytostatic therapeutic drug monitoring and occupational exposure assessment. TrAC Trends in Analytical Chemistry 2017;93:152-70. [DOI: 10.1016/j.trac.2017.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
156 Uppugunduri CR, Rezgui MA, Diaz PH, Tyagi AK, Rousseau J, Daali Y, Duval M, Bittencourt H, Krajinovic M, Ansari M. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. Pharmacogenomics J 2014;14:263-71. [PMID: 24165757 DOI: 10.1038/tpj.2013.38] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
157 Gaillard D, Shechtman LA, Millar SE, Barlow LA. Fractionated head and neck irradiation impacts taste progenitors, differentiated taste cells, and Wnt/β-catenin signaling in adult mice. Sci Rep 2019;9:17934. [PMID: 31784592 DOI: 10.1038/s41598-019-54216-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
158 Anderson JE, Trujillo M, McElroy T, Groves T, Alexander T, Kiffer F, Allen AR. Early Effects of Cyclophosphamide, Methotrexate, and 5-Fluorouracil on Neuronal Morphology and Hippocampal-Dependent Behavior in a Murine Model. Toxicol Sci 2020;173:156-70. [PMID: 31651976 DOI: 10.1093/toxsci/kfz213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Johnson GG, Lin K, Cox TF, Oates M, Sibson DR, Eccles R, Lloyd B, Gardiner L, Carr DF, Pirmohamed M, Strefford JC, Oscier DG, Gonzalez de Castro D, Else M, Catovsky D, Pettitt AR. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood 2013;122:4253-8. [DOI: 10.1182/blood-2013-07-516666] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
160 McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, Park JR. Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. J Clin Pharmacol 2009;49:88-102. [PMID: 18927240 DOI: 10.1177/0091270008325928] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
161 Tran AP, Ali Al-Radhawi M, Kareva I, Wu J, Waxman DJ, Sontag ED. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance. Front Immunol 2020;11:1376. [PMID: 32695118 DOI: 10.3389/fimmu.2020.01376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
162 Knickelbein JE, Armbrust KR, Kim M, Sen HN, Nussenblatt RB. Pharmacologic Treatment of Noninfectious Uveitis. Handb Exp Pharmacol 2017;242:231-68. [PMID: 27848029 DOI: 10.1007/164_2016_21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
163 Mahmoud AM, Germoush MO, Alotaibi MF, Hussein OE. Possible involvement of Nrf2 and PPARγ up-regulation in the protective effect of umbelliferone against cyclophosphamide-induced hepatotoxicity. Biomedicine & Pharmacotherapy 2017;86:297-306. [DOI: 10.1016/j.biopha.2016.12.047] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 20.5] [Reference Citation Analysis]
164 Hajdinák P, Szabó M, Kiss E, Veress L, Wunderlich L, Szarka A. Genetic Polymorphism of GSTP-1 Affects Cyclophosphamide Treatment of Autoimmune Diseases. Molecules 2020;25:E1542. [PMID: 32231024 DOI: 10.3390/molecules25071542] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Review of Clinical Pharmacology 2014;5:569-85. [DOI: 10.1586/ecp.12.39] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
166 Joy MS, La M, Wang J, Bridges AS, Hu Y, Hogan SL, Frye RF, Blaisdell J, Goldstein JA, Dooley MA, Brouwer KL, Falk RJ. Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol 2012;74:445-55. [PMID: 22380717 DOI: 10.1111/j.1365-2125.2012.04223.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
167 Bokhari TH, Roohi S, Hina S, Akbar MU, Sohaib M, Iqbal M. Synthesis, quality control, and bio-evaluation of 99m Tc-cyclophosphamide. Chem Biol Drug Des 2018;91:456-62. [PMID: 28886237 DOI: 10.1111/cbdd.13107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
168 Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, Mangat R, Joshi A, Visich J. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol 2012;52:1918-26. [PMID: 22235140 DOI: 10.1177/0091270011430506] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
169 Tran A, Bournerias F, Le Beller C, Mir O, Rey E, Pons G, Delahousse M, Tréluyer JM. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms. Br J Clin Pharmacol 2008;65:279-80. [PMID: 17875191 DOI: 10.1111/j.1365-2125.2007.03020.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
170 Labaki C, Rawadi E, Chebel R, Bakouny Z, Droz JP, Kattan JG. Anti-neoplastic agents for patients on peritoneal dialysis: A systematic review. Crit Rev Oncol Hematol 2020;150:102947. [PMID: 32294609 DOI: 10.1016/j.critrevonc.2020.102947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
171 Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, Roman-Gomez J, Prosper F, Martinez-Climent JA. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010;116:2531-42. [PMID: 20570860 DOI: 10.1182/blood-2010-02-268003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 7.1] [Reference Citation Analysis]
172 Kawakami T, Nakamura Y, Karibe H. Cyclophosphamide-Induced Morphological Changes in Dental Root Development of ICR Mice. PLoS One 2015;10:e0133256. [PMID: 26186337 DOI: 10.1371/journal.pone.0133256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
173 Knickelbein JE, Jaworski L, Hasan J, Kaushal P, Sen HN, Nussenblatt RB. Therapeutic options for the treatment of non-infectious uveitis. Expert Review of Ophthalmology 2015;10:359-73. [DOI: 10.1586/17469899.2015.1047826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
174 Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;320:72-80. [PMID: 17041008 DOI: 10.1124/jpet.106.112136] [Cited by in Crossref: 218] [Cited by in F6Publishing: 208] [Article Influence: 14.5] [Reference Citation Analysis]
175 de Barros Pontes L, Todaro J, Karnakis T, Weinschenker Bollman P, Fortunato Cardoso Santos B, Aliosha Kaliks R, Del Giglio A. Treatment of a frail older patient with diffuse large B-cell lymphoma on maintenance dialysis: attenuated immunochemotherapy and adapted care plan. Case Rep Oncol 2013;6:197-203. [PMID: 23626561 DOI: 10.1159/000350746] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
176 Ming Z, Yongqiang Z, Zijin Z, Yan X, Di C, Xiaoxin T. Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a CYP2B6*7 variant. Pharmacogenomics 2019;20:1119-24. [PMID: 31686598 DOI: 10.2217/pgs-2019-0093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
177 Tuchynskaya K, Volok V, Illarionova V, Okhezin E, Polienko A, Belova O, Rogova A, Chernokhaeva L, Karganova G. Experimental Assessment of Possible Factors Associated with Tick-Borne Encephalitis Vaccine Failure. Microorganisms 2021;9:1172. [PMID: 34072340 DOI: 10.3390/microorganisms9061172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Sun T, Xue M, Yang J, Pei Z, Zhang N, Qin K, Liang H. Metabolic regulation mechanism of fucoidan via intestinal microecology in diseases. J Sci Food Agric 2021;101:4456-63. [PMID: 33682122 DOI: 10.1002/jsfa.11202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Tian S, Jiang X, Tang Y, Han T. Laminaria japonica fucoidan ameliorates cyclophosphamide-induced liver and kidney injury possibly by regulating Nrf2/HO-1 and TLR4/NF-κB signaling pathways. J Sci Food Agric 2021. [PMID: 34689333 DOI: 10.1002/jsfa.11602] [Reference Citation Analysis]
180 Reis-Mendes A, Carvalho F, Remião F, Sousa E, Bastos ML, Costa VM. The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells. Biomolecules 2019;9:E98. [PMID: 30862114 DOI: 10.3390/biom9030098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. European Journal of Cancer 2011;47:1556-63. [DOI: 10.1016/j.ejca.2011.03.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
182 Dittrich C, Solska E, Manikhas A, Eniu A, Tjulandin S, Anghel R, Musib L, Frimodt-Moller B, Liu Y, Krejcy K, Láng I. A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer. Cancer Invest 2012;30:309-16. [PMID: 22468806 DOI: 10.3109/07357907.2012.658938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
183 Hall OM, Peer CJ, Fitzhugh CD, Figg WD. A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2018;1086:56-62. [PMID: 29656084 DOI: 10.1016/j.jchromb.2018.04.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
184 Arango M, Cardona D. Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. Biol Blood Marrow Transplant 2020;26:1492-6. [PMID: 32417488 DOI: 10.1016/j.bbmt.2020.04.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
185 Sarkar AA, Allyn DM, Delay RJ, Delay ER. Cyclophosphamide-Induced Inflammation of Taste Buds and Cytoprotection by Amifostine. Chem Senses 2021;46:bjab031. [PMID: 34161570 DOI: 10.1093/chemse/bjab031] [Reference Citation Analysis]
186 Bemer MJ, Sorror M, Sandmaier BM, O'Donnell PV, McCune JS. A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. Cancer Chemother Pharmacol 2013;72:607-18. [PMID: 23907443 DOI: 10.1007/s00280-013-2232-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
187 Huang WY, Hong JB, Chang M, Wang SY, Lai SF, Chien HF, Lin SJ. Lower proximal cup and outer root sheath cells regenerate hair bulbs during anagen hair follicle repair after chemotherapeutic injury. Exp Dermatol 2021;30:503-11. [PMID: 32781495 DOI: 10.1111/exd.14175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Huyan X, Lin Y, Gao T, Chen R, Fan Y. Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. International Immunopharmacology 2011;11:1293-7. [DOI: 10.1016/j.intimp.2011.04.011] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 5.8] [Reference Citation Analysis]
189 Ekhart C, Kerst JM, Rodenhuis S, Beijnen JH, Huitema ADR. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. Cancer Chemother Pharmacol 2009;63:375-9. [DOI: 10.1007/s00280-008-0757-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
190 Palmer AC, Chidley C, Sorger PK. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. Elife 2019;8:e50036. [PMID: 31742555 DOI: 10.7554/eLife.50036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
191 Van Laar JM. Immunosuppressive Drugs. Kelley and Firestein's Textbook of Rheumatology. Elsevier; 2017. pp. 983-998.e4. [DOI: 10.1016/b978-0-323-31696-5.00062-0] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
192 Buhl T, Bertsch HP, Raab BW, Kaune KM, Vasko R, Strutz F, Schön MP, Lippert U. Fulminant polyarteritis nodosa associated with acute myeloid leukaemia resulted in bilateral lower leg amputation. Rheumatology (Oxford) 2009;48:1170-2. [PMID: 19553374 DOI: 10.1093/rheumatology/kep173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Jensen SB, Mouridsen HT, Reibel J, Brünner N, Nauntofte B. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. Oral Oncology 2008;44:162-73. [DOI: 10.1016/j.oraloncology.2007.01.015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
194 Chen L, Xiong X, Hou X, Wei H, Zhai J, Xia T, Gong X, Gao S, Feng G, Tao X, Zhang F, Chen W. Wuzhi capsule regulates chloroacetaldehyde pharmacokinetics behaviour and alleviates high-dose cyclophosphamide-induced nephrotoxicity and neurotoxicity in rats. Basic Clin Pharmacol Toxicol 2019;125:142-51. [PMID: 30793490 DOI: 10.1111/bcpt.13211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
195 Ben-Menachem E. Review article: systemic lupus erythematosus: a review for anesthesiologists. Anesth Analg 2010;111:665-76. [PMID: 20601448 DOI: 10.1213/ANE.0b013e3181e8138e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
196 Smith DA, Obach RS, Williams DP, Park BK. Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity. Chemico-Biological Interactions 2009;179:60-7. [DOI: 10.1016/j.cbi.2008.09.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
197 Jin Y, Yu D, Tolleson WH, Knox B, Wang Y, Chen S, Ren Z, Deng H, Guo Y, Ning B. MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes. Biochem Pharmacol 2016;113:88-96. [PMID: 27311985 DOI: 10.1016/j.bcp.2016.06.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
198 Rossmann E, Österborg A, Löfvenberg E, Choudhury A, Forssmann U, von Heydebreck A, Schröder A, Mellstedt H. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study. Hum Vaccin Immunother 2014;10:3394-408. [PMID: 25483677 DOI: 10.4161/hv.29918] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
199 Mukherjee N, Carroll BL, Spees JL, Delay ER. Pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice. PLoS One 2013;8:e61607. [PMID: 23626702 DOI: 10.1371/journal.pone.0061607] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]